Tag: the war on (some) drugs

Key GOP Congressmen, Including Pro-Marijuana Legalization Member, Defend Effort to Ban Consumable Hemp Products

Key GOP congressional lawmakers—including one member who supports marijuana legalization—don’t seem especially concerned about provisions in a new spending bill that would put much of the hemp industry in jeopardy by banning most consumable products derived from the plant.

In interviews with Marijuana Moment, Congressional Cannabis Caucus co-chair Rep. Dave Joyce (R-OH) and House Agriculture Committee Chairman Glen Thompson (R-PA), as well as Rep. Lou Correa (D-CA), weighed in on the hemp language in the large-scale bill that cleared the the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies on Thursday.

Under the measure, hemp would be redefined under federal statute in a way that would prohibit cannabis products containing any “quantifiable” amount of THC or “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals” as THC.

While Joyce backs legalizing and regulating cannabis for adult use, he said the language from the 2018 Farm Bill that federally legalized hemp and its derivatives “has been the stepping stone for the gas station delivery of intoxicants, whether that’s hemp or chemically manufactured [products] or whatever other shit it is that they sell at gas stations.”

“And there’s no age limit on it. So you’re handcuffing the regular cannabis industry that has strict standards that they have to meet everywhere, and yet this industry has flourished,” he said, adding that problems with the current law have been “exacerbated by people because there are some allegations that [intoxicating hemp products are] cannabis. It’s not hemp anymore.”

The congressman also seemed to endorse a push in Ohio to make it so intoxicating hemp products could only be sold to adults at licensed marijuana dispensaries. He said he told Gov. Mike DeWine (R) that, regardless of his views on the issue, the problem is the “gas station stuff that the kids are getting that all these people are up in arms about.”

That said, Joyce said while he does feel the 2018 Farm Bill’s hemp provisions included a “loophole” that’s been exploited, he hasn’t read the text of the latest legislation yet.

“I’m all for regulating the industry… It has to be regulated so that only adults are getting it,” he said.

Keep reading

Chicago Police Recruit Allegedly Found with Cocaine in Pocket

A Chicago Police Department recruit found himself in hot water during a training exercise after allegedly possessing crack cocaine. This incident unfolded during a narcotics arrest training scenario, as reported by CWB Chicago. The recruit’s surprising explanation for the discovery of the illicit substance has raised eyebrows among officials.

The scenario was intended to be a routine exercise, with recruits practicing search techniques. According to the report, a recruit discovered real crack cocaine while searching a fellow recruit’s pocket. The suspect offered a curious defense, claiming the pants were not his own but borrowed from his brother, who is also in law enforcement.

The training exercise involved a trainer providing recruits with a baggie marked with blue stars, simulating heroin. However, the recruit found a different baggie, clear and knotted, containing four smaller bags adorned with green dollar signs. Each of these smaller bags reportedly contained suspected crack cocaine.

In response to the discovery, the trainer questioned the recruit about the contents of the knotted baggie. The recruit initially dismissed it as “trash” before offering his explanation about the ownership of the pants. This bizarre claim has left officials perplexed as they continue their investigation.

Keep reading

Nevada Lawmakers Pass Resolution Urging Congress To Reschedule Psychedelics And Expedite Research On Their Medical Benefits

The Nevada legislature has approved a joint resolution calling on Congress to reschedule certain psychedelics, streamline research and provide protections for people using the substances in compliance with state law.

After initially moving through the Senate and then the House with amendments, the Senate concurred to the other body’s changes and gave final approval to the proposal last Thursday.

SJR 10, from Sen. Rochelle Nguyen (D), has now been formally enacted and will be transmitted to President Donald Trump, Vice President JD Vance, House Speaker Mike Johnson (R) and all of the members of Nevada’s congressional delegation, as well as the heads of the Drug Enforcement Administration and National Institutes of Health.

The resolution cites research demonstrating the therapeutic potential of psychedelics in the treatment of serious mental health conditions and calls on the federal government to “reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA to a schedule that better reflects the therapeutic value, low potential for abuse and safety for use under medical supervision of those compounds.”

It also points out that there have been federal developments on the issue, including the Food and Drug Administration (FDA) designation of certain psychedelics as “breakthrough therapies” and research that’s being funded to explore the substances at the Department of Defense (DOD) and U.S. Department of Veterans Affairs (VA).

The measure urges Congress to increase funding for further research, establish a “streamlined process for approving and conducting research with psychedelic compounds,” and reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA under the Controlled Substances Act (CSA).

Further, it calls for the establishment of “legal protection against federal prosecution for individuals and entities complying with state law concerning the supervised adult use of psychedelic compounds and require states to enter research partnerships with the Attorney General under the Controlled Substances Act to study the public health outcomes of such state programs.”

The amendment adopted by the Assembly and now signed off on by the Senate “specifies that legal protections against federal prosecution shall be for individuals and entities who are compliant with state and local laws concerning the supervised adult use of psychedelic compounds,” Sen. James Ohrenschall (D) said on the floor.

Keep reading

Hotels See Significant Boost In Revenue Following Marijuana Legalization, New Study Shows

A new study exploring the impacts of adult-use marijuana legalization on the hospitality industry finds that “hotel revenue increases by 25.2% (or $63,671 monthly) due to dispensary legalization, with the effect continuing to grow even six years after legalization.”

The research article, published in the journal Production Operations and Management (POMS), draws its inferences from a review of data from Colorado, which authors say saw “a 7.9% increase in room night bookings and a 16.0% rise in daily room rates,” though impacts varied based on a number of factors.

“These findings are relevant for professionals in marketing, operations management, hospitality, tourism, and public policy,” the study says, noting that the “rapid expansion of the marijuana business presents both opportunities and challenges for the hotel industry.”

“On the one hand, recreational marijuana dispensaries could become attractions that entice travelers to visit places they might not otherwise explore. For instance, around 12% of US tourists have reported positive experiences with marijuana-related travel… On the other hand, the lingering social stigma surrounding marijuana could negatively affect businesses, including hotels, located near these dispensaries. This concern is underscored by a Colorado Office of Economic Development and International Trade (OEDIT 2019) report, which found that about 10% of US leisure travelers view Colorado as a less desirable destination because of recreational marijuana.”

Despite the apparently polarized feelings around traveling to jurisdictions where marijuana is legal, the study found that hotels seemed to perform better following the policy change.

Comparing hotels in Colorado to hotels in New Mexico, where cannabis was illegal during the study period, the team’s analysis found that “on average, monthly hotel revenue increases by 25.2% upon the legalization of recreational marijuana dispensaries, which is equivalent to a substantial increase of $63,671 per hotel.”

Keep reading

Federal Judge Allows Lawsuit Seeking Home Psilocybin Care To Proceed, Rejecting Oregon Officials’ Motion To Dismiss

More people in Oregon could eventually access legal psilocybin following a new federal court ruling in favor of plaintiffs who argued that the state’s first-in-the nation psilocybin law wrongfully prevents homebound patients from seeking care.

Four care providers—three licensed psilocybin facilitators and a physician specializing in advanced and terminal illnesses—sued the state about year ago, alleging that the state Psilocybin Services Act (PSA) discriminates against disabled individuals who can’t travel to designated service centers where the substance is administered.

The providers said they were told by the Oregon Health Authority (OHA) that there was no way to accommodate homebound patients under the state’s psilocybin law.

In an 12-page ruling issued late last month, District Judge Mustafa T. Kasubhai denied the state’s motion to dismiss the suit, opining that the plaintiffs have standing to bring the challenge and that a modification of the state’s psilocybin law to provide a reasonable accommodation to homebound patients under the federal Americans with Disabilities Act (ADA) would not violate principles of federalism.

“The Court agrees with Plaintiffs and finds that their requested remedy rests on physical access rather than use or distribution of a controlled substance in violation of state and federal laws,” the ruling says. “Plaintiffs do not ask the Court to order the provision of a controlled substance, as Defendants contend. Instead…Plaintiffs seek compliance with the ADA so that their disabled clients will have the same physical access to a service that is available to nondisabled individuals.”

Reached by email on Tuesday, plaintiffs’ attorney Kathryn Tucker, said she was pleased the court ruled in favor of the providers seeking to offer home psilocybin services.

“We are eager to ensure that homebound disabled and dying Oregonians can access psilocybin services, as they are among those most likely to benefit,” she wrote. “Opening access for these Oregonians will increase demand for psilocybin produced pursuant to the PSA as well as demand for services of facilitators, particularly those with expertise in providing care to disabled persons and those with advanced illness.”

“We hope to move this forward quickly now that the court has rejected the State’s effort to dismiss, recognizing that the ADA does apply to Oregon’s psilocybin program,” she added. “Because people with advancing illness may have little time left, delay in enabling access can mean that patients who might have obtained relief from debilitating anxiety and depression will die in unrelieved suffering.”

Notably, the new opinion, noted earlier by Psychedelic Week, does not order a specific remedy. It simply allows the underlying suit, Cusker v. Oregon Health Authority, to proceed toward a final decision.

Keep reading

GOP Congressional Committee Proposes Ban On Hemp Products With THC That Advocates Say Would Have ‘Devastating’ Impact On Industry

A GOP-led House committee has unveiled a spending bill that contains provisions that hemp stakeholders say would devastate the industry, prohibiting most consumable cannabinoid products that were federally legalized during the first Trump administration.

The House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies published the text of the legislation covering fiscal year 2026 just one day ahead of a scheduled Thursday markup.

The 138-page bill covers a wide range of issues, but for the hemp industry, there’s a section of particular concern that would redefine hemp under federal statute in a way that would prohibit cannabis products containing any “quantifiable” amount of THC or “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals” as THC.

That would effectively eliminate the most commonly marketed hemp products within the industry, as even non-intoxicating CBD items that are sold across the country typically contain trace amounts of THC. Under current law, those products are allowed if they contain no more than 0.3 percent THC by dry weight.

But the proposed policy being taken up by the subcommittee helmed by anti-marijuana Rep. Andy Harris (R-MD) would drastically change that. It would instead maintain the legal status of “industrial hemp” under a revised definition that allows for the cultivation and sale of hemp grown for fiber, whole grain, oil, cake, nut, hull, microgreens or “other edible hemp leaf products intended for human consumption.”

Keep reading

Texas Hemp Advocates Deliver 100,000+ Petitions To Governor’s Office, Urging Him To Veto THC Ban Bill

Texas hemp advocates and stakeholders are rallying in opposition to a bill the legislature passed to outlaw all consumable hemp-derived cannabinoid products containing any detectable THC—delivering more than 100,000 petition signatures asking Gov. Greg Abbott (R) to veto the measure.

“Senate Bill 3 was designed to destroy a vibrant and legitimate industry,” Cynthia Cabrera, president of Texas Hemp Business Council, which represents the state’s roughly $8 billion hemp industry, said in a press release. “The bill now awaits review by Governor Abbott. We respectfully urge him to consider the facts, listen to our appeal and make the logical decision to veto SB 3.”

At a press conference on Monday, Cabrera said she wanted to “address the misinformation, misdirection and maligning of this industry” by the bill sponsor, Sen. Charles Perry (D), and Lt. Gov. Dan Patrick (R), who serves as presiding officer of the Senate and strongly advocated for the legislation.

“SB 3 violates the very principles Texas prides itself on: small government, individual freedom and free enterprise,” she said. “Governor Abbott, we ask that you keep your promise to small businesses, to women entrepreneurs and to every Texan who values freedom.”

Keep reading

A Lot More Older Americans Are Now Using Marijuana, Federally Funded Study Shows

A new federally funded report published by the Journal of the American Medical Association (JAMA) finds that use of marijuana by U.S. adults 65 and older has increased considerably in recent years amid broader legal access for medical and recreational use.

Cannabis consumption had already been on the rise over the past couple of decades, the research letter says, with reported past-year consumption rising from 1.0 percent in 2005 to 4.2 percent in 2o18. The new findings, which draw on the National Survey on Drug Use and Health, show that past-month use has now climbed to 4.8 percent in 2021 and to 7.0 percent in 2023.

The growth in prevalence over the past few years was seen among nearly all demographic subsets, but it was especially strong among people who listed their race as “other,” women, white people, people with college or post-college degrees, those with higher-income, married people and those living in states with legal medical marijuana, the report says.

Data also showed that people with multiple chronic diseases also reported a recent increase in prevalence of use.

Some trends reveal what authors called “shifts in cannabis use by older adults.”

“Adults with the highest incomes initially had the lowest prevalence of cannabis use vs other income levels,” they said, for example, “but by 2023, they had the highest prevalence, which may indicate better access to medical cannabis given its costs.”

The rise in cannabis use among adults 65 and older in legal jurisdictions “highlights the importance of structural educational support for patients and clinicians in those states,” the report notes, pointing to potential complications in treating chronic disease.

It also flags that tobacco and excess alcohol use “continues to be high among older adults who use cannabis. However, these results do not suggest that concurrent use is changing.”

The report concludes by advising that clinicians “consider screening and educating older patients about potential risks of cannabis use.”

The new findings, by researchers at University of California, San Diego and New York University medical schools, were published as a research letter on Monday.

Along with the report, JAMA also published an editor’s note asserting that “existing therapeutic evidence for medical cannabis in older adults has been inconsistent across several conditions, with many studies suggesting possible benefits, while others finding limited benefit.”

It also highlights “apparent” potential harms that marijuana might cause older adults, including “increased risks of cardiovascular, respiratory, and gastrointestinal conditions, stroke, sedation, cognitive impairment, falls, motor vehicle injuries, drug-drug interactions, and psychiatric disorders.”

“Older adults require information on methods available for taking cannabis and age-specific dosing guidance,” the editor’s note says. “Health care professionals should recognize that older adults are increasingly using cannabis products and promote open and judgment-free conversations about its use.”

Overall, it says, the new research findings “underscore the need for more high-quality evidence evaluating the benefit to risk ratio of cannabis in older adults as well as the need for clinician support to prevent cannabis-related harm.”

Keep reading

Only One European Country’s Cannabis Policy Is Actually Undermining The Illicit Market

In the last several decades, Europe has made significant strides in its approach to legalized cannabis use, moving from strict criminalization and prohibition to decriminalization and legalized medical and adult-use models. In addition to expanding healthcare and adult-use access to cannabis use, it’s also important to discuss what impact these varying policies have in counteracting the foothold of illicit cannabis markets throughout the European Union.

Under E.U. law, many countries encounter hurdles in legalizing adult-use commercial cannabis, as they likely would be subject to penalties under the European Court of Justice. For this reason, several countries—including the Netherlands, Malta, Luxembourg, Switzerland and Germany—have taken unique approaches to cannabis policy.

Germany, however, stands out in terms of producing a measurable impact to push back against the illicit cannabis market.

The Netherlands: A Tolerance Model Without Market Control

Long seen as a pioneer, the Netherlands’ approach to cannabis is based on tolerance rather than legalization. Adults can purchase small quantities of cannabis from Dutch “coffee shops,” which are tolerated but not fully legalized. These shops are forced to source products from an illegal supply chain due to a lack of legal production.

In terms of impact, the tolerated model might seem like a considerable way to go, as every adult in the Netherlands can access coffee shops. However, in terms of control, product safety and regulation, the Dutch cannabis system is vulnerable, as the whole value chain is not regulated and the products are produced illegally for the coffee shops.

Due to the drawbacks of the tolerance model, the Netherlands has just initiated its Weed Experiment. The experiment will allow coffee shops in 10 municipalities to sell legally produced and supplied cannabis. A report on the results of the closed-loop experiment is expected for 2028.

Malta: Liberal on Paper, Constrained in Practice

Malta decriminalized cannabis use in 2015 and, in 2021, became the first European Union country to allow the cultivation and private personal use of cannabis. However, the market remains heavily restricted.

The government permits adult cultivation of cannabis (up to four plants) and personal possession of seven grams when away from home and 50 grams at home. The country also legalized nonprofit cannabis associations that can distribute cannabis to their members. These clubs are limited to 500 people, and membership is only available to residents. However, the public consumption, transportation and sale of cannabis are still banned and can result in fines.

With club membership strictly limited, public consumption outlawed and no other options for adults to legally purchase cannabis outside of the nonprofit associations, the market remains very limited. As of May 2025, no public information is available detailing the exact amount of cannabis provided by these associations to their members.

Luxembourg: Legalization Without Access

In 2021, Luxembourg legalized cannabis cultivation for adult use. However, it wasn’t until two years later, in 2023, that the country defined its legal cultivation and possession rules for personal use. Under the law, adults can grow up to four plants and possess three grams. However, consumption, transportation, and sale in public spaces are still banned and can result in fines.

As reported by the Luxembourg Times, 46.3 percent of the country’s residents have tried cannabis at least once in their lives, including 14.2 percent who have used the plant within the last year and 7.8 percent in the past month, according to an ILRES poll. Just under seven out of ten people who grow cannabis at home said they started cultivation after the government legalized home grow, amounting to just 11.5 percent of recent users.

Despite homegrow gaining moderate interest from residents after legalization, there has not been a significant growth in users, and this has not resulted in an explosion in the market. For now, the market remains stagnant and limited in counteracting illicit sellers due to the country’s lack of legalized sales marketplaces as well as restrictions on public consumption.

Switzerland: Research-Oriented but Limited in Scope

Switzerland has taken a scientific approach through pilot programs across seven major cities to determine the viability of cannabis legalization and controlled distribution within the country over 10 years.

While the pilot programs are set up to allow recreational cannabis commerce at a local level, in terms of true societal impact, this initial rollout does not serve as a solution to counteract the illicit cannabis market. This is mainly due to the limited availability of the majority of Swiss residents. Only Swiss residents who have previously established histories of using cannabis can purchase through the pilot program entities. These pilot programs are also limited to a maximum of a few hundred or a few thousand participants.

Germany: A Functional, Scalable Legal Medical Market

Germany’s cannabis market is widely hailed as one of Europe’s most progressive. On April 1, 2024, the country passed The Cannabis Act (CanG), reclassifying cannabis as a non-narcotic. Through this, administrative burdens were eased for medical cannabis patients and prescribing doctors. CanG also allows possession of up to 25 grams of cannabis and cultivation of up to 3 plants, and it permits the rollout of not-for-profit cannabis clubs.

In January 2025, my medical cannabis company, Bloomwell Group, released its “Cannabis 2024 in Germany: A new era for patients in Germany” report. According to the report, in December 2024, the number of prescriptions issued increased by a little less than 1,000 percent compared to March 2024, following the reclassification of cannabis. The rise of patients who are now able to access cannabis for various medical conditions signals a shift in the perception of cannabis being used for its wellness properties in the medical space.

Telemedical technology in the sector has also positively impacted growth and counteracted the illicit market. Telemedical platforms offer convenience for patients and the physicians who prescribe their treatment. This is extremely helpful to patients who are located in rural or isolated areas of Germany and have geographic limitations in accessing healthcare professionals for their medical needs.

The Bloomwell report also revealed that medical cannabis prices dropped to an all-time low by the end of 2024. During October and November 2024, select strains were available for just €3.99 per gram, a stark contrast to previous pricing models. These decreases are due to a steady supply and increased demand for medical cannabis as the number of self-paying patients continues to soar.

Such demand continues to open doors for international imports of medical cannabis to supply the growing market. Just in the first quarter of 2025, more than 37 tonnes of cannabis for medical or scientific purposes have been imported to Germany, according to the Federal Institute for Drugs and Medical Devices (BfArM).

Unlike other legalized markets, like California in the U.S., which fell victim to being dwarfed by a behemoth illicit market, the passage of CanG served as a catalyst to boom the German medical market, and with more patients able to access cannabis, prices of the plant actually decreased. This allowed the legalized medical market to stay competitive with the illicit market.

Keep reading

Trump Wants To Delete State Medical Marijuana Protections From Budget While Continuing To Block Cannabis Sales Legalization In D.C.

President Donald Trump is again proposing to remove existing protections for states that have legalized medical marijuana, while maintaining a ban that’s prevented Washington, D.C. from enacting a system of regulated adult-use cannabis sales.

As part of his budget request for the 2026 fiscal year sent to Congress on Friday, Trump is seeking to delete a longstanding rider that’s barred the Justice Department from using its funds to interfere in the implementation of state-level medical marijuana laws.

This is Trump’s first budget request of his second term, but during his first term he similarly called for its deletion each year of his presidency.

President Joe Biden, on the other hand, consistently proposed to continue the medical cannabis provision intact in his budget requests—though President Barack Obama, like Trump, had sought to delete it.

Congress has the final say on appropriations legislation language, however, and has not followed through on any president’s request to delete the medical marijuana protection since it was first enacted into law in 2014—though lawmakers have also declined to expand the protections to cover state recreational marijuana programs.

After signing prior appropriations bills into law that included the medical cannabis protection in contravention of his request to delete it, Trump on three occasions issued statements that specifically said his administration “will treat this provision consistent with the President’s constitutional responsibility to faithfully execute the laws of the United States”— implying he was reserving his right to ignore the rider.

The latest action in Trump’s new budget request will likely come as a disappointment to advocates and stakeholders, who have held out hope that the president would take a new direction on marijuana policy reform—especially after he endorsed rescheduling, industry banking access and a Florida cannabis legalization ballot initiative that ultimately fell short.

Keep reading